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Chikungunya and 
Dengue Viruses in 
Travelers 
To the Editor: Chikungunya vi-
rus (CHIKV), an arthropod-borne virus 
transmitted to humans by Aedes spp. 
mosquitoes, was ﬁ  rst isolated in Tanza-
nia (Tanganyika) in 1953 (1). Various 
outbreaks have since occurred in Af-
rica, Southeast Asia, and India (2).
CHIKV has recently been report-
ed in a large area in the Indian Ocean 
islands and the Indian subcontinent. 
After an outbreak in Kenya in 2004, 
other outbreaks occurred in early 2005 
on the Comoros Islands, Réunion, and 
other islands in the southwestern In-
dian Ocean; the epidemic then spread 
to India (3,4). Molecular analysis 
showed that the epidemic was caused 
by a variant of the Central/East Afri-
can CHIKV genotype (5,6).
Internet surveillance networks 
provided information on epidemics 
in real time, alerting clinicians in the 
industrialized world to the spread of 
CHIKV and enabling them to more 
easily diagnose infection among trav-
elers with fevers (7). We report results 
of diagnostic tests and analysis of pre-
dictors of infection among persons 
in Italy with symptoms suggestive of 
CHIKV infection who had traveled 
to potentially affected areas. Dengue 
virus (DENV) is endemic to many of 
these areas.
We studied travelers or migrants 
from areas to which CHIKV infection 
is endemic (i.e., sub-Saharan Africa) 
or areas currently affected by out-
breaks (i.e., the Indian Ocean islands, 
India) who had symptoms suggestive 
of infection (i.e., fever and arthralgia 
with or without a rash) from January 
2006 through March 2007. At least 1 
blood sample was collected from each 
patient and stored at –80°C before 
testing for CHIKV and DENV. Me-
dian lag between onset of symptoms 
and date of blood collection was 22 
days (range 3–179 days). Two sam-
ples (acute phase and convalescence 
phase) were available from 5 patients. 
Serologic diagnosis of CHIKV infec-
tion was determined by hemagglutina-
tion inhibition (HI) test and conﬁ  rmed 
by plaque-reduction neutralization test 
(8). Serodiagnosis of DENV infection 
was conducted by using the HI test 
and an immunoglobulin M ELISA 
(Focus Diagnostics, Cypress, CA, 
USA). A case-report form containing 
information about age, sex, countries 
visited, travel dates, and date of onset 
of symptoms was completed for each 
patient.
Seventy-six persons participated 
in the study; 55.3% were male, median 
age was 39 years (range 1–69 years), 
and most (80.3%) were Italian (Table). 
A total of 29 (38.2%) were positive for 
CHIKV, and 13 (17.1%) were positive 
for DENV; 34 (44.7%) were negative 
for both viruses. Of the 29 CHIKV-
positive persons, 22 (75.9%) had vis-
ited the Indian Ocean islands (Mauri-
tius, Réunion, and Madagascar), 5 had 
visited Asia, and 2 had visited Africa. 
Travelers from Indian Ocean islands 
had a higher risk for CHIKV infec-
tion than those who had visited Africa 
(odds ratio [OR] 11.0, 95% conﬁ  dence 
interval [CI] 1.60–119.13) or Asia (OR 
17.05, 95% CI 4.31–73.05). Persons 
who had visited Asia had a higher risk 
for DENV infection (OR 8.36; 95% CI 
1.58–81.73) than those who had vis-
ited other areas. 
The 5 persons who were infected 
with CHIKV in Asia had visited In-
dia (i.e., the most visited country [21 
travelers]). However, persons who 
visited the Indian Ocean islands had 
a higher risk of being CHIKV posi-
tive than those who had visited India 
(OR 8.8, 95% CI 2.09–39.86). A rash 
was associated with CHIKV infection 
and was >8× more likely to be report-
ed by CHIKV-positive persons than 
CHIKV-negative persons (OR 7.03, 
95% CI 2.23–22.93). Moreover, rash 
was observed in 65% of CHIKV-posi-
tive cases and 31% of DENV-posi-
tive cases, but the difference was not 
statistically signiﬁ  cant because of the 
small sample size (OR 4.28, 95% CI 
0.88–23.23). None of the other pa-
tient’s characteristics was associated 
with infection with CHIKV or DENV.
Table. Characteristics of 76 travelers studied 
Characteristic
Chikungunya virus–
positive, no. (%) 
Dengue virus–
positive, no (%) 
Seronegative,
no. (%) 
Total 29 (100.0)  13 (100.0)  34 (100.0) 
Sex 
  Male  17 (58.6)  6 (46.2)  19 (55.9) 
  Female  12 (41.4)  7 (53.8)  15 (44.1) 
Age, y 
  0–35  8 (27.6)  4 (30.8)  16 (47.0) 
  36–50  11 (37.9)  6 (46.1)  14 (41.2) 
  >50  10 (34.5)  3 (23.1)   4 (11.8) 
Days spent abroad 
 0  15 18 (62.1)  4 (30.8)  20 (58.8) 
  >15  11 (37.9)  9 (69.2)  14 (41.2) 
Area visited* 
  Africa  2 (6.9)  2 (15.4)  6 (17.6) 
  African islands  22 (75.9)  0 8 (23.5) 
  Asia  5 (17.2)  11 (84.6)  20 (58.8) 
Nationality 
  Italian  23 (79.3)  9 (69.2)  29 (85.3) 
  Other  6 (20.7)  4 (30.8)  5 (14.7) 
Rash
  Yes  19 (65.5)  4 (30.8)  6 (17.6) 
  No  10 (34.5)  9 (69.2)  28 (82.3) 
*Africa, continental Africa; African Islands, Western Indian Ocean islands; Asia, India and Southeast 
Asia. 
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only 5 patients had documented se-
roconversion for CHIKV. However, 
high titers were found in all but 1 pa-
tient (>1,280 in 21 patients and 640 in 
2 patients). This patient, who had a ti-
ter of 80, was an Italian who had prob-
ably not been previously exposed to 
CHIKV. Thus, the risk for misclassi-
ﬁ  cation was low. PCR for early detec-
tion of infection was not used because 
only 3 persons were tested within 10 
days of symptom onset. Two of these 
persons, who were tested 7 days after 
symptom onset, already had antibod-
ies to CHIKV.
In conclusion, a high proportion 
of travelers with symptoms of CHIKV 
infection who returned from areas with 
outbreaks of this infection or where this 
virus was endemic were seropositive. A 
lower proportion of patients had anti-
bodies to DENV. CHIKV-positive pa-
tients were more likely to have a rash 
than those negative for both CHIKV 
and DENV. As suggested by previous 
studies (9), a rash was more common 
among CHIKV-positive patients than 
in DENV-infected patients, but the dif-
ference was not signiﬁ  cant. Our study 
suggests that identiﬁ  cation of predictors 
of infection with CHIKV is feasible, al-
though it is complicated by cocircula-
tion of DENV in the same areas.
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Acinetobacter spp. 
in Gunshot Injuries
To the Editor: Challenges posed 
by  Acinetobacter spp. result from 
multidrug resistance, nosocomial 
spread, and hospital-wide outbreaks 
(1–3). We evaluated Acinetobacter 
spp. infections from gunshot injuries 
received during the April 2006 East 
Timor conﬂ   ict (for a description of 
these events and further reading, see 
http://en.wikipedia.org/wiki/2006_
East_Timorese_crisis). 
We reviewed records of 15 injured 
East Timorese police ofﬁ  cers. Median 
age was 29 years (range 25–45 years); 
13 were male. Typical injuries were 
from multiple high-velocity gunshots 
and shrapnel. All patients had under-
gone surgery for stabilization and 
wound debridement before evacuation 
to the Royal Darwin Hospital (RDH) 
in Australia; most had likely received 
antimicrobial drugs including ampi-
cillin, gentamicin, metronidazole, and 
ceftriaxone. They arrived at RDH a 
median of 3 days after injury (range 
2–12 days).
The patients were separated from 
other hospital inpatients on arrival; 
they were managed as a cohort, they 
had dedicated nursing staff, and bar-
rier contact precautions were prac-
ticed. However, the patients were not 
routinely screened for colonization 
with microbiologic organisms. Addi-
tional surgical management, includ-
ing further wound debridement, was 
performed on 12 of the 15 patients (11 
within 48 hours of arrival at RDH); 
intraoperative samples of bone, soft 
tissue, and wounds were submitted for 
culture.
From 13 patients (including all 
11 with gunshot wounds), 19 Acineto-
bacter spp. isolates were recovered. 
Acinetobacter spp. was cultured from 
deep wound tissue obtained during sur-
gery from 9 patients. Substantial anti-
microbial drug resistance was demon-
strated by automated testing (Vitek 2, 
bioMérieux, Marcy l’Etoile, France) 
(Table). All 19 Acinetobacter spp. iso-
lates were classiﬁ  ed as multidrug resis-
tant (resistant to >3 drug classes) (4). 
Isolates from 10 of the 13 culture-pos-
itive patients (12 of 19 isolates) were 
resistant to all tested drugs except me-
ropenem and amikacin. Susceptibility 
testing for tigecycline and tetracycline 
was not performed. No isolate was 
metallo-β-lactamase positive by phe-
notypic analysis according to tablet 
disk diffusion method using imipenem 
and imipenem plus EDTA Neo-Sen-
sitabs (Rosco Diagnostica, Taastrup, 
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